Company intelligence / Profile preview
HCW Biologics
- Ownership
- Public · HCWB
- Employees
- ~50
- Development stage
- Other
Overview
HCW Biologics has developed two proprietary drug discovery platforms generating multi-functional fusion proteins targeting immune modulation. Lead asset HCW9218 has shown early safety and activity signals in solid tumor patients refractory to chemotherapy. The company’s pipeline includes additional candidates targeting regulatory T cell expansion and immune stimulation. Clinical data are still emerging from ongoing early-phase trials.
- Therapeutic areas
- OncologyImmunologyCardiovascular
- Modalities
- Multi-functional fusion proteins (immunotherapies)Protein-based therapeuticsAntibody therapiesImmune cell engagers and stimulators
- Industry
- Biotech
Drug pipeline
12 assets11 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $361.5K
- Total revenue
- $54.2K
- Enterprise value
- $6.2M
Beyond the preview
Go deeper on HCW Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HCW Biologics.